Literature DB >> 27941417

Is There Any Association Between Use of Antidepressants and Preeclampsia or Gestational Hypertension?: A Systematic Review of Current Studies.

Faruk Uguz1.   

Abstract

OBJECTIVE: Hypertension in pregnant women is an important medical problem, which can cause morbidity and mortality in the fetus. This study reviewed the current literature examining the potential relationship between use of antidepressants during pregnancy and preeclampsia or gestational hypertension.
METHODS: PubMed was searched for English-language reports between January 1, 1995, and December 31, 2015, by using combinations of key words pregnancy, pregnancy complications, preeclampsia, gestational hypertension, and antidepressants. Studies that reported the diagnosis of preeclampsia or gestational hypertension and use of antidepressant were included in the review.
RESULTS: A total of 7 relevant studies that met the review criteria were examined. The studies reported that compared with nonusers adjusted relative risk of preeclampsia or gestational hypertension in antidepressant users was 1.28 to 1.53 for any antidepressant, 1.05 to 3.16 for selective serotonin reuptake inhibitors, 1.49 to 1.95 for selective serotonin-norepinephrine reuptake inhibitors, and 0.35 to 3.23 for tricyclic antidepressants. Consistently, antidepressant use during the second trimester of pregnancy was associated with increased risk of preeclampsia or gestational hypertension. However, possible contribution of severity, type, and comorbidity of underlying anxiety or depressive disorders is unclear in the current studies.
CONCLUSIONS: Although some studies have suggested a moderately increased risk in pregnancy-specific hypertensive disorders with antidepressant treatment, the current data do not allow a definitive conclusion on this topic, because the studies have many methodological limitations. In addition, the effects of untreated depression or anxiety disorders cannot be disentangled from the results.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27941417     DOI: 10.1097/JCP.0000000000000618

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  5 in total

1.  Maternal use of drugs and preeclampsia.

Authors:  Heidi Sahlman; Marjaana Koponen; Hani El-Nezami; Kirsi Vähäkangas; Leea Keski-Nisula
Journal:  Br J Clin Pharmacol       Date:  2019-12-15       Impact factor: 4.335

Review 2.  The impact of maternal prenatal mental health disorders on stillbirth and infant mortality: a systematic review and meta-analysis.

Authors:  Akilew A Adane; Helen D Bailey; Vera A Morgan; Megan Galbally; Brad M Farrant; Rhonda Marriott; Scott W White; Carrington Cj Shepherd
Journal:  Arch Womens Ment Health       Date:  2021-01-02       Impact factor: 3.633

3.  DNA methylation studies of depression with onset in the peripartum: A critical systematic review.

Authors:  Sarah Ellen Braun; Dana Lapato; Roy E Brown; Eva Lancaster; Timothy P York; Ananda B Amstadter; Patricia A Kinser
Journal:  Neurosci Biobehav Rev       Date:  2019-04-11       Impact factor: 8.989

4.  Prenatal Antidepressant Use and Risk of Adverse Neonatal Outcomes.

Authors:  Gretchen Bandoli; Christina D Chambers; Alan Wells; Kristin Palmsten
Journal:  Pediatrics       Date:  2020-06-08       Impact factor: 7.124

5.  Antidepressant use during pregnancy and the risk of developing gestational hypertension: a retrospective cohort study.

Authors:  Neily Zakiyah; Loes F Ter Heijne; Jens H Bos; Eelko Hak; Maarten J Postma; Catharina C M Schuiling-Veninga
Journal:  BMC Pregnancy Childbirth       Date:  2018-05-29       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.